Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021198999 - EPITOPE-BASED VACCINES FOR TREATMENT OF CORONAVIRUS ASSOCIATED DISEASES

Publication Number WO/2021/198999
Publication Date 07.10.2021
International Application No. PCT/IB2021/052781
International Filing Date 02.04.2021
IPC
C07K 11/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
11Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
A61K 38/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2770/20022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
20011Coronaviridae
20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • AXON NEUROSCIENCE SE [CY]/[CY]
Inventors
  • ZILKA, Norbert
  • KOVACECH, Branislav
  • KONTSEKOVA, Eva
  • SKRABANA, Rostislav
  • FILIPCIK, Peter
  • KOVAC, Andrej
  • NOVAK, Michal
Priority Data
63/005,02803.04.2020US
63/055,85423.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) EPITOPE-BASED VACCINES FOR TREATMENT OF CORONAVIRUS ASSOCIATED DISEASES
(FR) VACCINS À BASE D'ÉPITOPE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES AU CORONAVIRUS
Abstract
(EN) The disclosures described herein relate to polypeptides, antibodies, and compositions for use in the treatment and diagnosis of severe acute respiratory syndrome (SARS) coronavirus-associated diseases or disorders. Provided are new immunogenic compositions related to SARS CoV2 S protein and method of preventing and/or treating severe acute respiratory syndrome and other SARS-CoV-related disease, including COVID-19. Also provided are diagnostic reagents for the detection of SARS virus, SARS Cov2 S protein, a complex of SARS Cov2 S protein and ACE2, and/or severe acute respiratory syndrome or other SARS-CoV-related disease.
(FR) Les présentes inventions concernent des polypeptides, des anticorps et des compositions destinés à être utilisés dans le traitement et le diagnostic de maladies ou de troubles associés au coronavirus du syndrome respiratoire aigu sévère (SRAS). L'invention concerne de nouvelles compositions immunogènes associées à la protéine S du SARS et un procédé de prévention et/ou de traitement du syndrome respiratoire aigu sévère et d'autres maladies associées au SARS-CoV, y compris le COVID-19. L'invention concerne également des réactifs de diagnostic pour la détection du virus du SARS, le syndrome respiratoire aigu sévère (SRAS), un complexe de la protéine du SARS Cov2 S et de l'ACE2, et/ou du syndrome respiratoire aigu sévère ou d'une autre maladie liée au SARS-CoV.
Latest bibliographic data on file with the International Bureau